Genomics News & Analysis | Business 2.0
- AI in Genomics Explained: What Enterprises Need to Know in 2026
- Vertex Wins FDA Nod to Give Casgevy CRISPR Therapy to Toddlers
- AWS Showcases AI Role in Genomics at Symposium
- FDA: Gene-Editing Sponsors Can Reuse Platform Data Across Programs
- PacBio: Sub-$300 HiFi Genome Resets Long-Read Sequencing Economics
- Illumina vs Guardant vs Natera: The MRD Market Landscape 2026
- Illumina 2026: Distributed WGS MRD Kit Lands Ahead of ASCO
- Inside Illumina's 2026 Genomics Pivot — And What Rivals Are Doing
- The Quiet Genetics Infrastructure Shift Illumina and CRISPR Therapeutics
- Beyond the Sequencer: What Genomics ROI Actually Looks Like in 2026
- Genetics in 2026: Illumina and CRISPR Therapeutics Expose a Widening
- Why Pharma Groups Are Scaling Genomics in 2026, Led by Illumina and Roche
- Top Genetics Investment Priorities for 2026, According to Illumina, Thermo Fisher and Roche
- Why Biotech Companies Are Accelerating Genomics Adoption in 2026, Led by Illumina, Thermo Fisher and Ginkgo
- Why Healthcare Is Accelerating Genetics in 2026, Led by Roche and Illumina
- How Genomics Is Powering Precision Care in 2026, According to Illumina, Thermo Fisher and Gartner
- Why Genetics Is Becoming Core to Enterprise Strategy in 2026, According to Roche, Illumina and Deloitte
- Why Genomics Matters in 2026, According to Illumina and Gartner
- Top 10 Genetics Startups to Watch in 2026
- Why Enterprises Are Scaling Genetics Platforms in 2026, According to Roche, Illumina and Thermo Fisher